GlassScriptPhysician profile
Justin David Overhoff
NPI 1508331836
$4,545.03
in general payments reported to CMS, 2019-2025
38 companies · $1,326 in 2025
The $1,326 reported for 2025 was more than what 85% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,001 · 2022: $393 · 2023: $709 · 2024: $1,116 · 2025: $1,326.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,857 · Education: $294.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,857.21 |
| Education | $293.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $586.34 | 2023-2025 | Gemtesa, Orgovyx |
| Janssen Biotech, INC. | $535.93 | 2021-2025 | Erleada, Rybrevant, Carvykti |
| Abbvie INC. | $484.00 | 2021-2025 | |
| Astellas Pharma US INC | $459.17 | 2021-2025 | Xtandi, Myrbetriq |
| Dendreon Pharmaceuticals LLC | $317.95 | 2021-2024 | Provenge |
| Boston Scientific Corporation | $296.79 | 2024-2025 | Ams 700, Axonics, Lumenis Pulse 120h |
| Myriad Genetic Laboratories, INC. | $228.70 | 2021-2023 | Myrisk, Precisetumor, Bracanalysis Cdx |
| Accord Healthcare, INC. | $168.79 | 2024-2025 | |
| Ferring Pharmaceuticals INC. | $126.92 | 2025 | Adstiladrin |
| Tolmar Pharmaceuticals, INC. | $118.75 | 2021-2022 | |
| Endo Pharmaceuticals INC. | $113.26 | 2021-2024 | Xiaflex |
| Verity Pharmaceuticals INC. | $108.82 | 2024 | Trelstar |
| Sun Pharmaceutical Industries INC. | $106.93 | 2022-2023 | Yonsa |
| Merck Sharp & Dohme LLC | $96.85 | 2021-2025 | Lynparza, Keytruda |
| Bluewind Medical | $81.54 | 2025 | Revi |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $81.00 | 2021 | |
| Coloplast Corp | $50.38 | 2021-2022 | |
| Pfizer INC. | $49.49 | 2021-2025 | |
| Myovant Sciences INC. | $48.33 | 2021 | |
| Urovant Sciences INC | $45.02 | 2021 | |
| Travere Therapeutics, INC. | $37.34 | 2021-2022 | |
| Amgen INC. | $35.72 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $35.67 | 2021 | |
| Immunitybio, INC. | $34.08 | 2025 | |
| Olympus America INC. | $33.85 | 2021-2022 | |
| 180 Medical, INC. | $29.44 | 2024 | Gentlecath Glide |
| Procept Biorobotics Corporation | $24.96 | 2024 | Aquabeam System |
| Bioprotect Medical, INC. | $24.42 | 2025 | Bioprotect Balloon Implant System |
| Novartis Pharmaceuticals Corporation | $22.55 | 2021 | |
| Ambu INC. | $22.40 | 2021 | |
| Progenics Pharmaceuticals, INC. | $22.13 | 2024 | |
| Tolmar, INC. | $19.94 | 2023 | |
| Axonics, INC. | $18.57 | 2023 | Axonics |
| Caris Mpi, INC. | $18.10 | 2025 | Mi Cancer Seek |
| Urogen Pharma, INC. | $17.82 | 2021 | |
| Allergan, INC. | $16.23 | 2021 | |
| Foundation Medicine, INC. | $14.69 | 2021 | |
| Therapeuticsmd, INC. | $12.16 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Justin Overhoff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.